Myriad Genetics Company Profile (NASDAQ:MYGN)

About Myriad Genetics

Myriad Genetics logoMyriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Research Services
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MYGN
  • CUSIP: 62855J10
Key Metrics:
  • Previous Close: $19.05
  • 50 Day Moving Average: $16.62
  • 200 Day Moving Average: $18.66
  • 52-Week Range: $15.15 - $39.74
  • Trailing P/E Ratio: 21.53
  • Foreward P/E Ratio: 17.80
  • P/E Growth: -6.21
  • Market Cap: $1.30B
  • Outstanding Shares: 68,091,000
  • Beta: 0.26
Profitability:
  • Net Margins: 8.08%
  • Return on Equity: 12.02%
  • Return on Assets: 8.35%
Debt:
  • Debt-to-Equity Ratio: 0.28%
  • Current Ratio: 4.13%
  • Quick Ratio: 3.51%
Additional Links:
Companies Related to Myriad Genetics:

Analyst Ratings

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (?)
Ratings Breakdown: 3 Sell Ratings, 9 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 1.85)
Consensus Price Target: $27.00 (41.73% upside)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
Show:
DateFirmActionRatingPrice TargetDetails
2/8/2017Piper Jaffray CompaniesBoost Price Target$22.00View Rating Details
2/8/2017Jefferies Group LLCReiterated RatingHold$18.00View Rating Details
2/8/2017Ladenburg Thalmann Financial ServicesUpgradeSell -> NeutralView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingSell$15.00View Rating Details
12/27/2016Barclays PLCReiterated RatingEqual Weight$22.00View Rating Details
11/2/2016StephensDowngradeOverweight -> Equal WeightView Rating Details
10/10/2016Bank of America CorpReiterated RatingSellView Rating Details
8/21/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformView Rating Details
8/10/2016Morgan StanleyLower Price TargetUnderweight$25.00 -> $21.00View Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00View Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00View Rating Details
5/4/2016Leerink SwannReiterated RatingMarket Perform$44.00 -> $41.00View Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00View Rating Details
3/23/2016Goldman Sachs Group, Inc. (The)Boost Price Target$40.00View Rating Details
1/7/2016Cowen and CompanyBoost Price Target$40.00View Rating Details
9/20/2015William BlairReiterated RatingBuyView Rating Details
8/12/2015JMP SecuritiesLower Price TargetMarket Outperform$46.00 -> $40.00View Rating Details
5/28/2015Credit Suisse GroupReiterated RatingUnderperformView Rating Details
5/7/2015Cantor FitzgeraldReiterated RatingBuy$43.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Myriad Genetics (NASDAQ:MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017        
2/7/2017Q2 2017$0.24$0.26$189.72 million$196.50 millionViewListenView Earnings Details
11/1/2016Q117$0.25$0.23$172.31 million$177.50 millionViewN/AView Earnings Details
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.32$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.48$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
Current Year EPS Consensus Estimate: $0.99 EPS
Next Year EPS Consensus Estimate: $1.07 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.37$0.38$0.38
Q2 20164$0.41$0.43$0.42
Q3 20161$0.42$0.42$0.42
Q4 20162$0.36$0.45$0.41
Q1 20173$0.25$0.42$0.31
Q2 20173$0.23$0.46$0.33
Q3 20173$0.24$0.43$0.31
Q4 20173$0.25$0.38$0.31
Q1 20181$0.25$0.25$0.25
Q2 20181$0.27$0.27$0.27
Q3 20181$0.27$0.27$0.27
Q4 20181$0.28$0.28$0.28
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Myriad Genetics (NASDAQ:MYGN)
Insider Ownership Percentage: 6.20%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/23/2017John T HendersonDirectorBuy6,000$18.66$111,960.00View SEC Filing  
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.00View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.00View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline
4-traders.com logoMyriad Genetics : GeneSight Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical Therapeutics (NASDAQ:MYGN)
www.4-traders.com - February 24 at 9:15 AM
News IconGeneSight Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical Therapeutics (NASDAQ:MYGN)
www.pressreleasepoint.com - February 23 at 11:47 PM
us.rd.yahoo.com logoGeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical Therapeutics (NASDAQ:MYGN)
us.rd.yahoo.com - February 23 at 6:46 PM
nasdaq.com logoGeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical ... - Nasdaq (NASDAQ:MYGN)
www.nasdaq.com - February 23 at 8:33 AM
globenewswire.com logoMyriad's Prolaris® Test Significantly Improves the Risk Classification ... - GlobeNewswire (press release) (NASDAQ:MYGN)
globenewswire.com - February 18 at 5:56 PM
tmcnet.com logoMyriad's BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca's … (NASDAQ:MYGN)
www.tmcnet.com - February 17 at 4:57 PM
finance.yahoo.com logoMyriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer (NASDAQ:MYGN)
finance.yahoo.com - February 17 at 4:57 PM
finance.yahoo.com logo7:09 am Myriad Genetics announces new data demonstrating the utility of the Prolaris test to more accurately classify mortality risk and guide the management of newly diagnosed men with prostate cancer (NASDAQ:MYGN)
finance.yahoo.com - February 17 at 4:57 PM
finance.yahoo.com logoMyriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca's PARP Inhibitor, Olaparib (NASDAQ:MYGN)
finance.yahoo.com - February 17 at 4:57 PM
News IconImpact of Brokerage Rating on Myriad Genetics, Inc.(MYGN) - Highland Mirror (NASDAQ:MYGN)
www.highlandmirror.com - February 16 at 6:18 PM
istreetwire.com logoStocks Intraday Alert: Myriad Genetics, Inc. (MYGN), Brocade Communications Systems, Inc. (BRCD), Parsley Energy ... - iStreetWire (NASDAQ:MYGN)
istreetwire.com - February 14 at 9:11 PM
News IconPeeling Back The Layers on Myriad Genetics, Inc. (NASDAQ:MYGN): Analysts & Street Weigh In - Winfield Review (NASDAQ:MYGN)
winfieldreview.com - February 14 at 9:11 PM
capitalcube.com logoMyriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : February 14, 2017 (NASDAQ:MYGN)
www.capitalcube.com - February 14 at 9:11 PM
fool.com logoHere's Why Invitae Stock Jumped as Much as 16.3% This Morning (NASDAQ:MYGN)
www.fool.com - February 14 at 9:11 PM
News IconMyriad Genetics Inc MYGN Financial and Strategic SWOT Analysis Review [Updated: 01022017] Prices from USD $125 (NASDAQ:MYGN)
www.bioportfolio.com - February 11 at 11:51 PM
finance.yahoo.com logoMYRIAD GENETICS INC Financials (NASDAQ:MYGN)
finance.yahoo.com - February 11 at 6:50 PM
istreetwire.com logo3 Stocks in Focus: Zions Bancorporation (ZION), Myriad Genetics ... - iStreetWire (NASDAQ:MYGN)
istreetwire.com - February 11 at 12:42 AM
News IconMyriad Genetics (MYGN) Has Widest Revenue Beat in 2+ Years (NASDAQ:MYGN)
www.economiccalendar.com - February 10 at 7:40 PM
seekingalpha.com logoMyriad Genetics up 7.3%, headed to SmallCap 600 (NASDAQ:MYGN)
seekingalpha.com - February 10 at 6:42 PM
benzinga.com logoMyriad Genetics' Sell Thesis Is 'Largely Played Out' (NASDAQ:MYGN)
www.benzinga.com - February 9 at 7:48 PM
News IconMyriad Genetics, Inc. (MYGN) Issues Q3 Earnings Guidance (NASDAQ:MYGN)
mlbinjurynews.com - February 9 at 7:48 PM
capitalcube.com logoMyriad Genetics, Inc. :MYGN-US: Earnings Analysis: Q2, 2017 By the Numbers : February 9, 2017 (NASDAQ:MYGN)
www.capitalcube.com - February 9 at 7:47 PM
baystreet.ca logoMyriad Genetics (MYGN) Rises on Q2 Results (NASDAQ:MYGN)
www.baystreet.ca - February 9 at 12:38 AM
us.rd.yahoo.com logoEdited Transcript of MYGN earnings conference call or presentation 7-Feb-17 9:30pm GMT (NASDAQ:MYGN)
us.rd.yahoo.com - February 9 at 12:38 AM
us.rd.yahoo.com logoMyriad Genetics upgraded by Ladenburg Thalmann (NASDAQ:MYGN)
us.rd.yahoo.com - February 9 at 12:38 AM
thestreet.com logoGilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments (NASDAQ:MYGN)
us.rd.yahoo.com - February 9 at 12:38 AM
us.rd.yahoo.com logoMyriad Genetics: Fairly Valued? (NASDAQ:MYGN)
us.rd.yahoo.com - February 9 at 12:38 AM
biz.yahoo.com logoMYRIAD GENETICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:MYGN)
us.rd.yahoo.com - February 9 at 12:38 AM
News IconWhat Are the Technicals Saying About These Shares: Myriad Genetics Inc. (MYGN) - Benton Bulletin (NASDAQ:MYGN)
bentonbulletin.com - February 8 at 7:36 PM
fool.com logoHere's Why Myriad Genetics Stock Rose as Much as 16.2% This Morning (NASDAQ:MYGN)
www.fool.com - February 8 at 1:23 PM
News IconMyriad Genetics, Inc. (MYGN) Releases Earnings Results, Beats Expectations By $0.02 EPS – Sports Perspectives (NASDAQ:MYGN)
screenny.com - February 8 at 1:19 AM
seekingalpha.com logoMyriad Genetics (MYGN) Q2 2017 Results - Earnings Call Transcript (NASDAQ:MYGN)
seekingalpha.com - February 8 at 1:19 AM
seekingalpha.com logoMyriad Genetics FQ2 top line up 2%; hereditary cancer testing off 13%; earnings down 84%; cash flow ops down 65%; shares up 14% after hours on consensus beat (NASDAQ:MYGN)
seekingalpha.com - February 7 at 10:45 PM
News IconWhat are analysts saying about Myriad Genetics Inc’s (MYGN) future? (NASDAQ:MYGN)
simplywall.st - February 7 at 8:18 PM
rttnews.com logoMyriad Genetics Inc. Profit Drops 48% In Q2 (NASDAQ:MYGN)
www.rttnews.com - February 7 at 8:18 PM
us.rd.yahoo.com logoMyriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results (NASDAQ:MYGN)
us.rd.yahoo.com - February 7 at 8:18 PM
us.rd.yahoo.com logo4:15 pm Myriad Genetics beats by $0.02, beats on revs; guides Q3 EPS in-line, revs in-line; guides FY17 EPS in-line, revs in-line (NASDAQ:MYGN)
us.rd.yahoo.com - February 7 at 8:18 PM
sg.finance.yahoo.com logoMyriad beats Street 2Q forecasts (NASDAQ:MYGN)
sg.finance.yahoo.com - February 7 at 8:18 PM
News IconMarket Review: Focusing on These Shares: Myriad Genetics Inc. (MYGN) - Piedmont Register (NASDAQ:MYGN)
piedmontregister.com - February 7 at 3:16 PM
biz.yahoo.com logoQ2 2017 Myriad Genetics Inc Earnings Release - After Market Close (NASDAQ:MYGN)
biz.yahoo.com - February 7 at 9:10 AM
News IconMyriad Genetics, Inc. (MYGN) Set to Announce Earnings on Tuesday – Sports Perspectives (NASDAQ:MYGN)
screenny.com - February 6 at 6:49 PM
News IconLearn details of the Myriad Genetics Inc (MYGN) - product pipeline analysis, 2016 update (NASDAQ:MYGN)
www.whatech.com - February 3 at 7:29 PM
einnews.com logoMyriad Genetics Inc. Therapeutic and Drug Pipeline Review H2 (NASDAQ:MYGN)
brazilbusiness.einnews.com - February 3 at 12:37 AM
News IconWhat is the Street Saying About Myriad Genetics, Inc. (NASDAQ:MYGN)? - Aiken Advocate (NASDAQ:MYGN)
aikenadvocate.com - February 1 at 7:47 PM
News IconMA Watch on Shares of Myriad Genetics Inc. (MYGN) - Market Point (NASDAQ:MYGN)
mtptnews.com - January 31 at 12:27 AM
News IconWhat The Charts Are Saying About Myriad Genetics, Inc. (NASDAQ:MYGN) - The Tribune (NASDAQ:MYGN)
lakecitytribune.com - January 28 at 11:52 PM
News IconActive Trading Watch on Shares of Myriad Genetics Inc. (MYGN) - Springdale Times (NASDAQ:MYGN)
springdaletimes.com - January 26 at 10:33 PM
News IconAnalysts Sentiment on Myriad Genetics, Inc. (MYGN) - Highland Mirror (NASDAQ:MYGN)
www.highlandmirror.com - January 26 at 10:33 PM
globenewswire.com logoMyriad to Announce Fiscal Second-Quarter 2017 Financial Results ... - GlobeNewswire (press release) (NASDAQ:MYGN)
globenewswire.com - January 26 at 1:17 AM
nasdaq.com logoImplied Volatility Surging for Myriad Genetics (MYGN) Stock Options - Nasdaq (NASDAQ:MYGN)
www.nasdaq.com - January 26 at 1:17 AM

Social

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Where is Myriad Genetics' stock going? Where will Myriad Genetics' stock price be in 2017?

13 equities research analysts have issued 1 year target prices for Myriad Genetics' stock. Their forecasts range from $15.00 to $47.00. On average, they anticipate Myriad Genetics' stock price to reach $27.00 in the next twelve months.

When will Myriad Genetics announce their earnings?

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

Who owns Myriad Genetics stock?

Myriad Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (14.92%), State Street Corp (5.25%), Frontier Capital Management Co. LLC (4.44%), Renaissance Technologies LLC (3.94%), Dimensional Fund Advisors LP (2.42%) and Disciplined Growth Investors Inc. MN (2.01%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert.

Who sold Myriad Genetics stock? Who is selling Myriad Genetics stock?

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Baillie Gifford & Co., Renaissance Technologies LLC, S&T Bank PA, Marshall Wace LLP, Pinnacle Associates Ltd., Guggenheim Capital LLC and GSA Capital Partners LLP. Company insiders that have sold Myriad Genetics stock in the last year include Alexander Ford, Gary A King and John T Henderson.

Who bought Myriad Genetics stock? Who is buying Myriad Genetics stock?

Myriad Genetics' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Two Sigma Investments LP, Frontier Capital Management Co. LLC, Senzar Asset Management LLC, State Street Corp, FMR LLC, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main and Dimensional Fund Advisors LP. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade.

How do I buy Myriad Genetics stock?

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Myriad Genetics stock cost?

One share of Myriad Genetics stock can currently be purchased for approximately $19.05.

Myriad Genetics (NASDAQ:MYGN) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Earnings History Chart

Earnings by Quarter for Myriad Genetics (NASDAQ:MYGN)

Dividend History Chart

Dividend Payments by Quarter for Myriad Genetics (NASDAQ:MYGN)

Last Updated on 2/24/2017 by MarketBeat.com Staff